Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: TheBusDriver who wrote (10036)	7/3/2002 8:38:53 AM
From: axial	Read Replies (1) \| Respond to of 14101

Ah, Wayne, there's the problem: "So this might shed some light on the sales problem in the UK. Sure wish I had asked the brand name of the other product. My GP is quite willing to perscribe Pennsaid for me, however it is not his first choice. He was aware of the different delivery system but did not seem to see any benefit, or enough, to change products." That's the crux of the matter, that everyone (DMX and investors) missed in the UK question. The "bottleneck" at the physician, and the woeful acceptance for a new topical for OA. This is why I've been cautioning about whoever the new distributor in the UK will be - let's not get carried away, again. It's still a tough sell. When people like you walk in and ask for the product, use the product - and say "This stuff is GREAT!", one would think that would be enough to turn the tide. But in fact, a whole lot of stick-in-the-mud physicians are refusing to consider Pennsaid as anything more than "just another topical". It's going to be a long, slow haul for sales in the UK and EU, IMO. I think the superior efficacy of Pennsaid, aided by spillover from the possible JnJ US marketing efforts will cause a slow, steady gain in sales. But it ain't gonna be easy, IMO. Regards, Jim